EA201890648A2 - Диоксолановые аналоги уридина для лечения рака - Google Patents
Диоксолановые аналоги уридина для лечения ракаInfo
- Publication number
- EA201890648A2 EA201890648A2 EA201890648A EA201890648A EA201890648A2 EA 201890648 A2 EA201890648 A2 EA 201890648A2 EA 201890648 A EA201890648 A EA 201890648A EA 201890648 A EA201890648 A EA 201890648A EA 201890648 A2 EA201890648 A2 EA 201890648A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer treatment
- dioxolane
- uridine analogues
- analogues
- dioxolane uridine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- -1 DIOXOLANE URIDINE ANALOGUES Chemical class 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В изобретении предложены соединения формулыгде Rпредставляет собой ORили NRR; Rпредставляет собой F; Rпредставляет собой H или C(=O)R; Rпредставляет собой H; Rпредставляет собой C-C-алкил; Rпредставляет собой фенил или нафтил, где фенил возможно замещен 1 R; и другие переменные являются такими, как определено в формуле изобретения, которые являются полезными в лечении рака, а также связанные с ними аспекты.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450983 | 2014-08-25 | ||
| SE1550858 | 2015-06-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201890648A2 true EA201890648A2 (ru) | 2018-08-31 |
| EA201890648A3 EA201890648A3 (ru) | 2019-02-28 |
| EA033300B1 EA033300B1 (ru) | 2019-09-30 |
Family
ID=54014804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790328A EA031106B1 (ru) | 2014-08-25 | 2015-08-24 | Диоксолановые аналоги уридина для лечения рака |
| EA201890648A EA033300B1 (ru) | 2014-08-25 | 2015-08-24 | Диоксолановые аналоги уридина для лечения рака |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790328A EA031106B1 (ru) | 2014-08-25 | 2015-08-24 | Диоксолановые аналоги уридина для лечения рака |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US10144750B2 (ru) |
| EP (2) | EP3572410B1 (ru) |
| JP (2) | JP6663424B2 (ru) |
| KR (2) | KR102396905B1 (ru) |
| CN (4) | CN107074826B (ru) |
| AU (2) | AU2015308988C1 (ru) |
| BR (1) | BR112017003898B1 (ru) |
| CA (2) | CA3128645C (ru) |
| CY (1) | CY1122945T1 (ru) |
| DK (2) | DK3186244T3 (ru) |
| EA (2) | EA031106B1 (ru) |
| ES (2) | ES2796089T3 (ru) |
| HR (1) | HRP20201023T1 (ru) |
| HU (2) | HUE059640T2 (ru) |
| IL (2) | IL250344B (ru) |
| MX (1) | MX369649B (ru) |
| MY (1) | MY188089A (ru) |
| NZ (2) | NZ729118A (ru) |
| PH (2) | PH12017500184B1 (ru) |
| PL (2) | PL3572410T3 (ru) |
| PT (2) | PT3572410T (ru) |
| SG (3) | SG11201701172SA (ru) |
| WO (1) | WO2016030335A1 (ru) |
| ZA (1) | ZA201802864B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201701172SA (en) * | 2014-08-25 | 2017-03-30 | Medivir Ab | Dioxolane analogues of uridine for the treatment of cancer |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| PT3386998T (pt) * | 2015-12-11 | 2021-11-30 | NuCana plc | Síntese diastereosseletiva de derivados fosfato e do pró-fármaco gemcitabina nuc-10311 |
| US10456413B2 (en) * | 2016-03-02 | 2019-10-29 | Medivir Aktiebolag | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| CN106432328B (zh) * | 2016-09-14 | 2019-03-22 | 江苏福瑞生物医药有限公司 | 一种索非布韦中间体的制备方法 |
| KR20190085976A (ko) * | 2016-11-18 | 2019-07-19 | 뉴로바이브 파마슈티컬 에이비 | 미토콘드리아 프로톤 이오노포어의 간 프로드러그 |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
| CA3129585A1 (en) * | 2019-02-18 | 2020-08-27 | Medivir Aktiebolag | Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| CN110964057B (zh) * | 2019-12-25 | 2022-05-06 | 东南大学 | 一种利用微流体反应装置制备索非布韦中间体的方法 |
| CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| MXPA03003278A (es) * | 2000-10-13 | 2005-07-01 | Shire Biochem Inc | Analogos de dioxolano para suministro intercelular mejorado. |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| WO2007106450A2 (en) * | 2006-03-10 | 2007-09-20 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy |
| CN101534835B (zh) * | 2006-09-01 | 2012-05-30 | 佐治亚大学研究基金会 | 用于癌症的L-OddC的前药 |
| PL216525B1 (pl) * | 2006-10-17 | 2014-04-30 | Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk | 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| JP2017504572A (ja) * | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
| SG11201701172SA (en) * | 2014-08-25 | 2017-03-30 | Medivir Ab | Dioxolane analogues of uridine for the treatment of cancer |
-
2015
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active IP Right Grant
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active IP Right Grant
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en active Application Filing
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
-
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184B1/en unknown
-
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
-
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
-
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-06-29 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
-
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890648A2 (ru) | Диоксолановые аналоги уридина для лечения рака | |
| EA201990221A1 (ru) | 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов | |
| EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| EA201892147A1 (ru) | Бициклические соединения | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
| EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
| EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
| EA201792535A1 (ru) | Гетероциклические амиды в качестве ингибиторов киназ | |
| EA201890373A1 (ru) | Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами | |
| EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| EA201591382A1 (ru) | Ингибиторы гистондеметилаз | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |